Pharma and Life Sciences COO Jobs in San Francisco

05:42 / local laboratory pickup

The sample reaches the central laboratory on time and nobody can prove which protocol clock governed the handoff

A participant visits a local healthcare provider rather than the principal research site. The collection kit is correct, the courier scan is present and the central laboratory accepts the sample. The local provider used a superseded instruction, the investigator learned of the visit after dispatch, and the sponsor's vendor portal shows every milestone green.

The COO should not interpret the result or replace investigator oversight. The operating decision is to stop an apparently successful chain from becoming an untraceable clinical record. That requires named responsibility for instruction version, local-provider qualification, participant scheduling, investigational-product custody where relevant, courier exception, source transfer, investigator review and sponsor visibility.

FDA's September 2024 final guidance discusses decentralized elements such as remote visits, in-home visits and local healthcare providers. The technology can move an activity. It does not collapse sponsor, investigator and other responsibilities into the vendor running the platform.

This page was compiled on 17 August 2026. It identifies no company, participant, product, protocol, facility, vendor or vacancy.

Nine-custodian strip

Participant, investigator, sponsor, local provider, courier, laboratory, depot, platform and quality owner must not become one generic vendor lane

Ask a candidate to mark when the chain stops, who communicates with the participant, which record becomes authoritative and how the sponsor sees recurrence. A successful shipment with the wrong instruction remains a failed operating system.

Operating constitution

The Charter must name who owns the work, who owns the regulated decision and who can stop the clock between them

Identify the parent, IND sponsor or applicant, investigators, research sites, local providers, laboratories, CROs, technology vendors, manufacturers, quality units, depots, wholesalers, third-party logistics providers and California licensees relevant to the mandate. Contract name and legal responsibility are not interchangeable.

Allocate board, CEO, COO, clinical, medical, safety, regulatory, quality, manufacturing, supply, technology, finance and legal decisions. The COO may own integration, capacity, vendor performance and escalation while another function retains protocol, patient, submission or release authority.

Name the first participant handoff, first batch disposition interface, first supply signal, first California custody decision and the evidence access required to govern them. A promise to hold vendors accountable is empty if the COO cannot inspect the state before a service level turns red.

Market zero / no implied opening

Zero authorised Charters support no represented COO vacancy, USD package, clinical timetable or product-supply claim

Pharma and Life Sciences COO Jobs in San Francisco is a mandate-intelligence page. Public trial information, an inspection classification, licence application, vendor announcement or supply report does not identify a confidential appointment.

Reward varies with development and commercial stage, sponsor scope, clinical footprint, manufacturing network, quality condition, supply responsibility, transaction agenda, team, location and equity instrument. Zero authorised comparators cannot support a precise range.

Membership funds assessment, bounded verification and consent-led matching. It creates no employer access, product authority, interview or appointment.

Sponsor-to-vendor control room

The CRO completes every contracted monitoring visit and the sponsor cannot see the risk pattern across sites

FDA's sponsor-responsibility materials describe selecting qualified investigators, providing information, ensuring proper monitoring, maintaining an effective IND and informing FDA and participating investigators of significant new risks under the applicable framework. The actual responsibilities belong to the regulated parties, not to the COO by title.

Give the candidate a synthetic study with on-time visits, recurring consent deviations, slow query closure and different escalation thresholds across regions. The CRO dashboard measures contractual completion, while no sponsor view joins severity, recurrence, investigator response and participant consequence.

The COO should build the integration without practising medicine or rewriting regulatory judgments. Define source systems, event taxonomy, owner, clock, stop threshold, cross-site signal, specialist review and board visibility. Then amend the vendor measure so completed activity and unresolved risk cannot cancel each other.

Decentralized element rehearsal

A home visit improves participation and creates four new places where identity, product, data and urgent escalation can separate

Use a fictional protocol with remote consent support, a home visit, local laboratory testing and direct shipment of investigational product where the qualified design permits. The operating map should locate participant identity, scheduling, provider qualification, training, product accountability, sample custody, data transfer, investigator oversight and safety escalation.

FDA's final decentralized-elements guidance provides recommendations and discusses roles, remote activities and operational considerations. Guidance does not make every decentralised approach appropriate, nor does it transfer the investigator's participant responsibilities to the COO.

Now make the technology platform unavailable during an urgent report and the courier deliver to an outdated address. Ask which manual record controls, who contacts whom, how the participant is protected and when activity pauses. Resilience must be designed before convenience is scaled.

Quality independence test

The batch is needed for the next treatment window and the quality unit's unresolved question is now the critical path

Provide a synthetic batch with acceptable headline tests, an open investigation, scarce replacement stock and a scheduled patient need. Operations can expose options, time, capacity and consequence. It cannot turn supply urgency into independent disposition authority.

The candidate should define material state, investigation owner, evidence missing, quality decision, regulatory and clinical interfaces, alternative supply, patient or study consequence, communication and executive escalation. Ask what work can proceed without prejudging the outcome and what must stop.

FDA explains CGMP as systems for the design, monitoring and control of manufacturing processes and facilities, with quality built through robust operations rather than final testing alone. A strong COO treats the quality boundary as part of operating design, not as an obstacle to schedule.

Maturity without a badge

The site closes deviations on time and its operating system still rewards recurrence that never breaches the target

FDA says CDER is establishing a Quality Management Maturity programme aimed at practices beyond CGMP requirements, and its current page describes a 2026 prototype assessment protocol evaluation opportunity. Do not convert that evolving programme into a universal public rating or legal requirement.

Give the candidate a fictional site whose closure metric is green while repeat events migrate between equipment, shifts and products. Ask for recurrence families, weak-signal review, management behaviour, knowledge transfer, preventive action, supplier input, capacity pressure and quality-unit challenge.

The COO's evidence is not a maturity slogan. It is a case where the operating target changed before a failure forced it, independent quality judgment remained intact and the improvement survived a leadership or volume transition.

Shortage signal ladder

Yield falls for three lots before demand exceeds supply, leaving the company time to act only if operations names the signal early

FDA's drug-shortage materials describe manufacturing and quality problems, delays and discontinuations as possible causes, and explain that manufacturers provide much of the information used by the agency. Section 506C materials address notice for certain covered products and events. Qualified regulatory teams must determine the actual duty.

Use a synthetic commercial product with a falling yield, one qualified site, limited safety stock and uncertain demand. Build signal, confirmation, notification assessment, mitigation, allocation, customer communication, investigation and recovery as separate clocks.

Do not wait for a database label to begin internal governance. Nor should the COO announce a shortage or substitute regulatory judgment. The operating contribution is reliable, early product-and-site evidence that lets accountable functions decide before every option becomes emergency action.

California custody fork

The logistics provider holds no title, the wholesaler directs the sale and the operating dashboard calls both organisations distribution vendors

The California Board of Pharmacy describes a wholesaler licence as required before a firm distributes, brokers or transacts the sale or return of dangerous drugs or devices in California. It describes a third-party logistics provider as coordinating warehousing or logistics on behalf of another party without taking ownership or directing sale or disposition.

Provide a fictional chain with manufacturer, title owner, wholesaler, 3PL, nonresident facility, return and destruction route. The candidate maps product identity, title, possession, direction, sale, licence, designated supervision where applicable, transaction data, quality state and exception ownership.

Actual licensing depends on current facts and law. The assessment tests whether the COO sees the distinction before contracting, system configuration and physical flow harden an incorrect assumption.

Ten operating reversals

Build a COO dossier from handoffs that failed early enough to be redesigned, not from volume that happened to ship

For each, state operating condition, legal entity, personal authority, professional owners, source record, failed assumption, stop point, action, aggregate outcome, recurrence and residual weakness. Explain what the COO did not decide.

References should verify conduct under conflicting clocks. The most useful observer may be a quality leader who refused release, an investigator who received late visibility or a vendor leader whose service measure was rewritten.

Candidate questions

Direct answers for operators considering a confidential Bay Area life sciences mandate

Acceptance release rehearsal

Follow one participant record and one product unit across the real organisation before accepting the transformation mandate

Map the parent, sponsor or applicant, investigators, sites, local providers, laboratories, CROs, technology vendors, manufacturers, quality units, depots, wholesalers, logistics providers and California licensees. Name contracts, legal responsibilities, data rights and stop authority.

Choose one trial handoff. Trace instruction version, participant schedule, provider qualification, product or kit custody, sample, courier, laboratory receipt, source transfer, investigator review, sponsor monitoring and exception. Introduce a platform outage and outdated instruction.

Choose one manufacturing handoff. Trace material, process state, test, deviation, investigation, quality decision, inventory, shipment and intended use. Introduce a scarce replacement and resist any assumption that operating urgency can release the batch.

Review quality-management evidence. Separate current CGMP obligations and site facts from FDA's evolving QMM programme and prototype work. Identify repeat-event families, weak signals and management behaviours before relying on a maturity claim.

Run a synthetic supply interruption from yield signal through qualified regulatory notification assessment, mitigation, allocation, communication and recovery. Confirm which entity and accountable officer own each action.

Trace one California commercial unit through manufacturer, title owner, wholesaler, third-party logistics provider, nonresident operations, return and destruction. Verify actual licensing with qualified legal and regulatory owners.

Agree the COO's clinical, quality, regulatory, supply, technology, finance and board interfaces, data access, vendor rights, escalation clocks and first ninety-day docket. Complete clinical, regulatory, quality, licence, legal, identity, reference, background and compensation diligence before resignation.